Flubromazolam

Flubromazolam is a triazolobenzodiazepine — a structural fusion of the triazolo ring system of alprazolam and triazolam with the fluorine and bromine substitution pattern of flubromazepam. This combination produces one of the most potent benzodiazepine-class compounds encountered in research chemical markets, with activity reported at doses of 0.05–0.5 mg (50–500 micrograms) — doses so small that inaccurate measurement creates serious overdose risk. Community members have described effects beginning at doses in the 50–100 microgram range; typical doses causing full sedation are in the 0.1–0.5 mg range.

The combination of very high potency, triazolo-ring-associated pronounced amnesia, and the extended duration inherited from its bromazepam-related parent structure creates an exceptionally dangerous compound for uncontrolled use. A small amount of powder on a scale could represent multiple active doses; the margin between an anxiolytic dose and one producing unconsciousness is narrow; and the amnestic effects mean users may not accurately recall what they consumed.

Two Reddit posts in the database touch on flubromazolam, reflecting its more niche use compared to etizolam or flualprazolam. The harm reduction community has consistently flagged flubromazolam as among the highest-risk designer benzodiazepines — not because its pharmacology is qualitatively different from other benzodiazepines, but because the combination of sub-milligram active doses, pronounced amnesia, and extended duration creates multiple compounding risks for even experienced benzodiazepine users.